Metabolism of vabicaserin in mice, rats, dogs, monkeys, and humans

Drug Metabolism and Disposition

Volumn 38, Issue 12, 2010, Pages 2266-2277

  Tong, Zeen ^a   Chandrasekaran, Appavu ^a   DeMaio, William ^a   Espina, Robert ^a   Lu, Wei ^a   Jordan, Ronald ^a   Scatina, JoAnn ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMIC ACID DERIVATIVE; IMINE; NITRONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SEROTONIN AGONIST; UNCLASSIFIED DRUG; VABICASERIN; VABICASERIN C 14; WAY 280107;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG EXCRETION; DRUG METABOLISM; DRUG RETENTION; DRUG STRUCTURE; FEMALE; GLUCURONIDATION; HUMAN; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; METABOLISM; METABOLITE; MONKEY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION; PRIORITY JOURNAL; SAFETY; SPECIES; URINARY EXCRETION;

ANIMALS; ANTIPSYCHOTIC AGENTS; AZEPINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; GLUCURONIDES; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; HYDROXYLATION; MACACA FASCICULARIS; MALE; MICE; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS; MUS; RATTUS;

EID: 78649552301     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033670     Document Type: Article

References (7)

1. Di Giovanni G, Di Matteo V, Di Mascio M, and Esposito E (2000) Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35:53-61.
2. Di Matteo V, Di Giovanni G, Di Mascio M, and Esposito E (1999) SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38:1195-1205.
3. Dunlop J, Zhang J, Watts S, Ramamoorthy S, Harrison B, Barrett JE, Magolda R, Schecheter L, Pangalos MN, Stack G, et al. (2006) In vitro pharmacological profile of SCA-136, a novel 5-HT2C receptor selective agonist. 36th Annual Meeting for the Society for Neuroscience; 2006 Oct 14-18; Atlanta, GA. Society for Neuroscience, Washington, DC.
4. Marquis KL, Dunlop J, Ramamoorthy S, Beyer CE, Lin Q, Brennan J, Piesla MJ, Ashby CRJ, Harrison B, Magolda R, et al. (2006) SCA-136: a novel 5-HT2C receptor agonist possessing atypical antipsychotic-like effects in preclinical models. 36th Annual Meeting for the Society for Neuroscience; 2006 Oct 14-18; Atlanta, GA. Society for Neuroscience, Washington, DC.
5. Millan MJ, Dekeyne A, and Gobert A (1998) Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37:953-955.
6. Spahn-Langguth H and Benet LZ (1992) Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24:5-47.
7. Tong Z, Chandrasekaran A, DeMaio W, Jordan R, Li H, Moore R, Poola N, Burghart P, Hultin T, and Scatina J (2010) Species differences in the formation of vabicaserin carbamoyl glucuronide. Drug Metab Dispos 38:581-590.